RxDoctor Payments Data

David Zink, MD

Gastroenterology · Holland, MINPI 1386690162

Payments from drug & device makers

$4,857in general payments, 2019–2025

Across 238 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$874
  • Takeda Pharmaceuticals U.S.A., Inc.$811
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$564
  • Pfizer$235
  • Sanofi$181
  • plus $975 from 15 others

What the payments were for

  • Food & beverage$4,71797%
  • Education$1403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,857 in reported general payments places this provider in the 65th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$40,213
Medicare patients
186
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide43$24,332
Mesalamine17$11,516
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg280$6,878
Pantoprazole Sodium232$2,717
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,350
Lubiprostone16$2,317
CholestyramineCholestyramine (With Sugar)25$2,240
Dexlansoprazole DrDexlansoprazole12$1,987
Budesonide DrBudesonide23$1,672
Dicyclomine Hcl51$889
Lactulose14$830
Omeprazole41$482
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg24$410
Nadolol13$402
Ondansetron OdtOndansetron11$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,217$24,33243 claims
Braintree Laboratories, Inc.Sutab$12$2,35015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →